Hematology TimesAntidote reverses effects of apixaban, rivaroxaban in healthy subjectsNovember 12, 2015Thrombosis
Hematology TimesFDA: Long-term clopidogrel doesn’t affect risk of deathNovember 7, 2015ThrombosisPharmacy
Oncology PracticeFDA finds long-term clopidogrel does not increase death or cancer risksNovember 6, 2015ThrombosisPatient & Survivor Care
Hematology NewsIdarucizumab approved as first agent to reverse a novel oral anticoagulantOctober 16, 2015Thrombosis
Hematology TimesHealth Canada approves drug for acquired hemophilia AOctober 16, 2015ThrombosisPharmacy